arketamine

Novamind Raises CA$10M, Heads Towards CSE Listing Toronto-based psychedelics company Novamind Ventures announced the closing of a private placement for CA$10 million ($7.6 million). Last week, the company confirmed that it successfully inked a definitive amalgamation agreement with Hinterland...

In February 2020, scientists in Brazil performed an open-label study on arketamine, a variant of ketamine. The pilot trial, conducted by the Federal University of Bahia, was performed on seven subjects suffering from treatment-resistant depression. It found evidence that arketamine might produce...